Cargando…

Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer

Neoadjuvant therapy (NAT) is increasingly applied in pancreatic ductal adenocarcinoma (PDAC); however, accurate prediction of therapeutic response to NAT remains a pressing clinical challenge. Cancer-cell-derived sialylated immunoglobulin G (SIA-IgG) was previously identified as a prognostic biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Ming, Shoucair, Sami, Liao, Quan, Qiu, Xiaoyan, Kinny-Köster, Benedict, Habib, Joseph R., Ghabi, Elie M., Wang, Junke, Shin, Eun Ji, Leng, Sean X., Ali, Syed Z., Thompson, Elizabeth D., Zimmerman, Jacquelyn W., Shubert, Christopher R., Lafaro, Kelly J., Burkhart, Richard A., Burns, William R., Zheng, Lei, He, Jin, Zhao, Yupei, Wolfgang, Christopher L., Yu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389326/
https://www.ncbi.nlm.nih.gov/pubmed/36799816
http://dx.doi.org/10.1097/JS9.0000000000000200
_version_ 1785082274026356736
author Cui, Ming
Shoucair, Sami
Liao, Quan
Qiu, Xiaoyan
Kinny-Köster, Benedict
Habib, Joseph R.
Ghabi, Elie M.
Wang, Junke
Shin, Eun Ji
Leng, Sean X.
Ali, Syed Z.
Thompson, Elizabeth D.
Zimmerman, Jacquelyn W.
Shubert, Christopher R.
Lafaro, Kelly J.
Burkhart, Richard A.
Burns, William R.
Zheng, Lei
He, Jin
Zhao, Yupei
Wolfgang, Christopher L.
Yu, Jun
author_facet Cui, Ming
Shoucair, Sami
Liao, Quan
Qiu, Xiaoyan
Kinny-Köster, Benedict
Habib, Joseph R.
Ghabi, Elie M.
Wang, Junke
Shin, Eun Ji
Leng, Sean X.
Ali, Syed Z.
Thompson, Elizabeth D.
Zimmerman, Jacquelyn W.
Shubert, Christopher R.
Lafaro, Kelly J.
Burkhart, Richard A.
Burns, William R.
Zheng, Lei
He, Jin
Zhao, Yupei
Wolfgang, Christopher L.
Yu, Jun
author_sort Cui, Ming
collection PubMed
description Neoadjuvant therapy (NAT) is increasingly applied in pancreatic ductal adenocarcinoma (PDAC); however, accurate prediction of therapeutic response to NAT remains a pressing clinical challenge. Cancer-cell-derived sialylated immunoglobulin G (SIA-IgG) was previously identified as a prognostic biomarker in PDAC. This study aims to explore whether SIA-IgG expression in treatment-naïve fine needle aspirate (FNA) biopsy specimens could predict the pathological response (PR) to NAT for PDAC. METHODS: Endoscopic ultrasonography-guided FNA biopsy specimens prior to NAT were prospectively obtained from 72 patients with PDAC at the Johns Hopkins Hospital. SIA-IgG expression of PDAC specimens was assessed by immunohistochemistry. Associations between SIA-IgG expression and PR, as well as patient prognosis, were analyzed. A second cohort enrolling surgically resected primary tumor specimens from 79 patients with PDAC was used to validate the prognostic value of SIA-IgG expression. RESULTS: SIA-IgG was expressed in 58.3% of treatment-naïve FNA biopsies. Positive SIA-IgG expression at diagnosis was associated with unfavorable PR and can serve as an independent predictor of PR. The sensitivity and specificity of SIA-IgG expression in FNA specimens in predicting an unfavorable PR were 63.9% and 80.6%, respectively. Both positive SIA-IgG expression in treatment-naïve FNA specimens and high SIA-IgG expression in surgically resected primary tumor specimens were significantly associated with shorter survival. CONCLUSIONS: Assessment of SIA-IgG on FNA specimens prior to NAT may help predict PR for PDAC. Additionally, SIA-IgG expression in treatment-naïve FNA specimens and surgically resected primary tumor specimens were predictive of the prognosis for PDAC.
format Online
Article
Text
id pubmed-10389326
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-103893262023-08-01 Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer Cui, Ming Shoucair, Sami Liao, Quan Qiu, Xiaoyan Kinny-Köster, Benedict Habib, Joseph R. Ghabi, Elie M. Wang, Junke Shin, Eun Ji Leng, Sean X. Ali, Syed Z. Thompson, Elizabeth D. Zimmerman, Jacquelyn W. Shubert, Christopher R. Lafaro, Kelly J. Burkhart, Richard A. Burns, William R. Zheng, Lei He, Jin Zhao, Yupei Wolfgang, Christopher L. Yu, Jun Int J Surg Original Research Neoadjuvant therapy (NAT) is increasingly applied in pancreatic ductal adenocarcinoma (PDAC); however, accurate prediction of therapeutic response to NAT remains a pressing clinical challenge. Cancer-cell-derived sialylated immunoglobulin G (SIA-IgG) was previously identified as a prognostic biomarker in PDAC. This study aims to explore whether SIA-IgG expression in treatment-naïve fine needle aspirate (FNA) biopsy specimens could predict the pathological response (PR) to NAT for PDAC. METHODS: Endoscopic ultrasonography-guided FNA biopsy specimens prior to NAT were prospectively obtained from 72 patients with PDAC at the Johns Hopkins Hospital. SIA-IgG expression of PDAC specimens was assessed by immunohistochemistry. Associations between SIA-IgG expression and PR, as well as patient prognosis, were analyzed. A second cohort enrolling surgically resected primary tumor specimens from 79 patients with PDAC was used to validate the prognostic value of SIA-IgG expression. RESULTS: SIA-IgG was expressed in 58.3% of treatment-naïve FNA biopsies. Positive SIA-IgG expression at diagnosis was associated with unfavorable PR and can serve as an independent predictor of PR. The sensitivity and specificity of SIA-IgG expression in FNA specimens in predicting an unfavorable PR were 63.9% and 80.6%, respectively. Both positive SIA-IgG expression in treatment-naïve FNA specimens and high SIA-IgG expression in surgically resected primary tumor specimens were significantly associated with shorter survival. CONCLUSIONS: Assessment of SIA-IgG on FNA specimens prior to NAT may help predict PR for PDAC. Additionally, SIA-IgG expression in treatment-naïve FNA specimens and surgically resected primary tumor specimens were predictive of the prognosis for PDAC. Lippincott Williams & Wilkins 2023-02-16 /pmc/articles/PMC10389326/ /pubmed/36799816 http://dx.doi.org/10.1097/JS9.0000000000000200 Text en © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/)
spellingShingle Original Research
Cui, Ming
Shoucair, Sami
Liao, Quan
Qiu, Xiaoyan
Kinny-Köster, Benedict
Habib, Joseph R.
Ghabi, Elie M.
Wang, Junke
Shin, Eun Ji
Leng, Sean X.
Ali, Syed Z.
Thompson, Elizabeth D.
Zimmerman, Jacquelyn W.
Shubert, Christopher R.
Lafaro, Kelly J.
Burkhart, Richard A.
Burns, William R.
Zheng, Lei
He, Jin
Zhao, Yupei
Wolfgang, Christopher L.
Yu, Jun
Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer
title Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer
title_full Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer
title_fullStr Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer
title_full_unstemmed Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer
title_short Cancer-cell-derived sialylated IgG as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer
title_sort cancer-cell-derived sialylated igg as a novel biomarker for predicting poor pathological response to neoadjuvant therapy and prognosis in pancreatic cancer
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10389326/
https://www.ncbi.nlm.nih.gov/pubmed/36799816
http://dx.doi.org/10.1097/JS9.0000000000000200
work_keys_str_mv AT cuiming cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT shoucairsami cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT liaoquan cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT qiuxiaoyan cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT kinnykosterbenedict cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT habibjosephr cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT ghabieliem cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT wangjunke cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT shineunji cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT lengseanx cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT alisyedz cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT thompsonelizabethd cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT zimmermanjacquelynw cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT shubertchristopherr cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT lafarokellyj cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT burkhartricharda cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT burnswilliamr cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT zhenglei cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT hejin cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT zhaoyupei cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT wolfgangchristopherl cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer
AT yujun cancercellderivedsialylatediggasanovelbiomarkerforpredictingpoorpathologicalresponsetoneoadjuvanttherapyandprognosisinpancreaticcancer